Axel Dignass
Overview
Explore the profile of Axel Dignass including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
6142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
DAmico F, Magro F, Dignass A, Al Awadhi S, Gutierrez Casbas A, Queiroz N, et al.
Expert Rev Gastroenterol Hepatol
. 2024 Sep;
18(8):421-430.
PMID: 39225555
Introduction: Although there are well-defined guidelines for the management of mild-to-moderate ulcerative colitis (UC), there are still unmet needs. For this reason, we conducted an international expert consensus to standardize...
12.
Panaccione R, Ma C, Jairath V, Dignass A, Joshi N, Clark R, et al.
J Crohns Colitis
. 2024 Aug;
19(2).
PMID: 39212931
Background: Endoscopic remission has emerged as an important treatment target in Crohn's disease (CD) and has been associated with improvement in long-term outcomes. We examined the relationship between achievement of...
13.
Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignass A, Ehehalt R, et al.
Z Gastroenterol
. 2024 Aug;
62(8):1229-1318.
PMID: 39111333
No abstract available.
14.
Sands B, Danese S, Chapman J, Gurjar K, Grieve S, Thakur D, et al.
Inflamm Bowel Dis
. 2024 Jul;
31(3):857-877.
PMID: 39083264
Background: Healing in Crohn's disease is complex and difficult to measure due to incongruencies between clinical symptoms and disease states. Mucosal healing (MH) and transmural healing (TH) are increasingly used...
15.
Kobayashi T, Dignass A, Roblin X, Takatori Y, Kaise T, Oortwijn A, et al.
Intest Res
. 2024 Jul;
23(1):65-75.
PMID: 39026439
Background/aims: Obtaining and maintaining corticosteroid-free remission are important goals of treatment for ulcerative colitis (UC). Characteristics associated with achieving corticosteroid-free remission were assessed in filgotinib-treated patients in SELECTION, a 58-week,...
16.
Danese S, Dignass A, Matsuoka K, Ferrante M, Long M, Redondo I, et al.
J Crohns Colitis
. 2024 Jun;
18(11):1845-1856.
PMID: 38869019
Background And Aims: Ulcerative colitis [UC], a chronic inflammatory bowel disease, may manifest with symptoms of increased stool frequency [SF], rectal bleeding [RB], bowel urgency [BU], abdominal pain [AP], and...
17.
Bettenworth D, Baker M, Fletcher J, Jairath V, Lu C, Bemelman W, et al.
Nat Rev Gastroenterol Hepatol
. 2024 Jun;
21(8):572-584.
PMID: 38831007
Fibrostenosis of the small bowel is common in patients with Crohn's disease. No consensus recommendations on definition, diagnosis and management in clinical practice are currently available. In this Consensus Statement,...
18.
DAmico F, Gomollon F, Bamias G, Magro F, Targownik L, Leitner C, et al.
United European Gastroenterol J
. 2024 May;
12(6):705-716.
PMID: 38733307
Background: Crohn's disease and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) characterized by a progressive nature of the disease resulting in subsequent intestinal damage, limited efficacy of current treatments...
19.
Lorenz P, Dignass A, Kucharzik T, Jansen P
Z Gastroenterol
. 2024 May;
62(5):e470-e476.
PMID: 38718807
No abstract available.
20.
Schmidt C, Stallmach A, Sturm A, Bachmann O, Helwig U, Koletzko S, et al.
Z Gastroenterol
. 2024 Apr;
62(4):517-534.
PMID: 38599579
No abstract available.